Literature DB >> 11330452

Epidemiology of ovarian cancer: a summary review.

C La Vecchia1.   

Abstract

Ovarian cancer is among the five leading sites for cancer incidence and mortality in women from developed countries. Its incidence and mortality rates have, however, been declining over the last few decades following the introduction of oral contraceptives, which - together with parity - are the best recognized protective factor for the disease. Late menopause and irregular menstrual cycles may also reduce the risk, while the role of hormone replacement therapy in menopause and fertility treatments is still unclear. Cosmetic talc use and some aspect of diet (i.e. saturated fats, refined carbohydrates) have been associated with increased risk, in some--though not all--studies), while vegetable consumption appears to be inversely related to risk. These issues remain open to debate. Women with a family history of ovarian and breast cancer in first-degree relatives are also at increased risk, but family history accounts for only 4-5% of cases. Most ovarian cancers are therefore environmental in origin and consequently, at least in principle, avoidable.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11330452     DOI: 10.1097/00008469-200104000-00002

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  15 in total

1.  Dietary fat, fiber, and carbohydrate intake and endogenous hormone levels in premenopausal women.

Authors:  Xiaohui Cui; Bernard Rosner; Walter C Willett; Susan E Hankinson
Journal:  Horm Cancer       Date:  2010-10       Impact factor: 3.869

2.  Parity and risk of lung cancer in women.

Authors:  Jessica K Paulus; Kofi Asomaning; Peter Kraft; Bruce E Johnson; Xihong Lin; David C Christiani
Journal:  Am J Epidemiol       Date:  2010-01-31       Impact factor: 4.897

3.  Urban-rural differences of gynaecological malignancies in Egypt (1999-2002).

Authors:  S Dey; A Hablas; I A Seifeldin; K Ismail; M Ramadan; H El-Hamzawy; M L Wilson; M Banerjee; P Boffetta; J Harford; S D Merajver; A S Soliman
Journal:  BJOG       Date:  2009-12-16       Impact factor: 6.531

4.  GPR30 predicts poor survival for ovarian cancer.

Authors:  Harriet O Smith; Hugo Arias-Pulido; Dennis Y Kuo; Tamara Howard; Clifford R Qualls; Sang-Joon Lee; Claire F Verschraegen; Helen J Hathaway; Nancy E Joste; Eric R Prossnitz
Journal:  Gynecol Oncol       Date:  2009-06-06       Impact factor: 5.482

Review 5.  RSK in tumorigenesis: connections to steroid signaling.

Authors:  T S Karin Eisinger-Mathason; Josefa Andrade; Deborah A Lannigan
Journal:  Steroids       Date:  2010-01-04       Impact factor: 2.668

6.  Chlamydia trachomatis and Mycoplasma genitalium plasma antibodies in relation to epithelial ovarian tumors.

Authors:  Annika Idahl; Eva Lundin; Margaretha Jurstrand; Urban Kumlin; Fredrik Elgh; Nina Ohlson; Ulrika Ottander
Journal:  Infect Dis Obstet Gynecol       Date:  2011-07-28

7.  Multiple miscarriages are associated with the risk of ovarian cancer: results from the European Prospective Investigation into Cancer and Nutrition.

Authors:  Marieke G M Braem; N Charlotte Onland-Moret; Leo J Schouten; Roy F P M Kruitwagen; Annekatrin Lukanova; Naomi E Allen; Petra A Wark; Anne Tjønneland; Louise Hansen; Christina Marie Braüner; Kim Overvad; Françoise Clavel-Chapelon; Nathalie Chabbert-Buffet; Birgit Teucher; Anna Floegel; Heiner Boeing; Antonia Trichopoulou; George Adarakis; Maria Plada; Sabina Rinaldi; Veronika Fedirko; Isabelle Romieu; Valeria Pala; Rocco Galasso; Carlotta Sacerdote; Domenico Palli; Rosario Tumino; H Bas Bueno-de-Mesquita; Inger Torhild Gram; Oxana Gavrilyuk; Eiliv Lund; Maria-José Sánchez; Catalina Bonet; Maria-Dolores Chirlaque; Nerea Larrañaga; Aurelio Barricarte Gurrea; Jose R Quirós; Annika Idahl; Nina Ohlson; Eva Lundin; Karin Jirström; Salma Butt; Konstantinos K Tsilidis; Kay-Tee Khaw; Nick Wareham; Elio Riboli; Rudolf Kaaks; Petra H M Peeters
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

8.  No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families.

Authors:  S Guedaoura; S Pelletier; W D Foulkes; P Hamet; J Simard; N Wong; Z El Haffaf; J Chiquette; M Dorval
Journal:  Curr Oncol       Date:  2017-12-20       Impact factor: 3.677

9.  Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas.

Authors:  Naifu Liu; Xiugui Sheng; Yi Liu; Xiaoling Zhang; Jinming Yu
Journal:  Onco Targets Ther       Date:  2013-06-05       Impact factor: 4.147

10.  Intramammary lymph node metastasis in a patient with ovarian carcinoma and a brief review of the literature.

Authors:  Lutfiye Demir; Cigdem Erten; Seyran Ceri Yigit; Alper Can; Ahmet Dirican; Vedat Bayoglu; Yuksel Kucukzeybek; Isil Somali; M Oktay Tarhan
Journal:  Contemp Oncol (Pozn)       Date:  2012-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.